# US 2004/0024307 A1 · Para-hydrogen labeled agents and their use in magnetic resonance imaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024307 A1
- Document ID: US20040024307A1
- Status: Published application
- Kind: A1
- Application number: 10/395,002
- Filed: 2003-03-24
- Published: 2004-02-05
- Earliest claimed: 1997-11-12
- Assignees: Amersham Health AS
- Inventors: Klaes Golman; Oskar Axelsson; Haukur Johanneson; Charlotte Olofsson; Sven Mansson; Stefan Petersson
- Web page: https://patentgrep.com/patent/US20040024307A1

## CPC

- A61K 49/06: Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K 49/08: characterised by the carrier
- A61K 49/10: Organic compounds
- A61K 49/18: characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K 49/1815: {compo-inhalant, e.g. breath tests}
- G01R 33/5601: {involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent}
- G01R 33/62: using double resonance (G01R33/24 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)

## Abstract

The invention provides a method of magnetic resonance investigation of a sample, said method comprising: (i) reacting para-hydrogen enriched hydrogen with a hydrogenatable MR imaging agent precursor containing a non-hydrogen non-zero nuclear spin nucleus to produce a hydrogenated MR imaging agent; (ii) administering said hydrogenated MR imaging agent to said sample; (iii) exposing said sample to radiation of a frequency selected to excite nuclear spin transitions of said non-zero nuclear spin nucleus in said hydrogenated MR imaging agent; (v) detecting magnetic resonance signals of said non-zero nuclear spin nucleus from said sample; and (vi) optionally, generating an image or biological functional data or dynamic flow data from said detected signals.

## Claims

### Claim 1

A method of magnetic resonance investigation of a sample, said method comprising:
(i) reacting para-hydrogen enriched hydrogen with a hydrogenatable MR imaging agent precursor containing a non-hydrogen non zero nuclear spin nucleus to produce a hydrogenated MR imaging agent;
(ii) administering said hydrogenated MR imaging agent to said sample;
(iii) exposing said sample to radiation of a frequency selected to excite nuclear spin transitions of said non-zero nuclear spin nucleus in said hydrogenated MR imaging agent;
(v) detecting magnetic resonance signals of said non-zero nuclear spin nucleus from said sample; and
(vi) optionally, generating an image or biological functional data or dynamic flow data from said detected signals.

### Claim 2 (depends on 1)

A method as claimed in claim 1 wherein said enriched hydrogen has a more than 45% proportion of para-hydrogen.

### Claim 3 (depends on 1)

A method as claimed in claim 1 wherein said enriched hydrogen has a more than 90° proprtion of para-hydrogen.

### Claim 4

A method as claimed in any of the preceding claims wherein said MR imaging agent precursor contains nuclei selected from F, Li, C, N, Si and P nuclei.

### Claim 5 (depends on 4)

A method as claimed in claim 4 wherein said non-zero nuclear spin nucleus is selected from 13C, 15N and 29Si.

### Claim 6 (depends on 5)

A method as claimed in claim 5 wherein said non-zero nuclear spin nucleus is 13C.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method as claimed in any one of claims 1 to 6 wherein said non-zero nuclear spin nucleus is present at a level greater than its natural isotopic abundance.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method as claimed in any one of claims 1 to 7 wherein said precursor contains a hydrogenatable unsaturated carbon-carbon bond.

### Claim 9 (depends on 8)

A method as claimed in claim 8 wherein said non-zero nuclear spin nucleus is present in said precursor one or two bonds distant from said unsaturated bond.

### Claim 10 (depends on 9)

A method as claimed in claim 9 wherein said nucleus one or two bonds distant from said unsaturated bond is only directly bonded to atoms which in their predominant isotopic state have zero nuclear spin.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method as claimed in any one of claims 1 to 10 wherein in said MR imaging agent the coupling constant (J) between said non-zero spin nucleus and a proton deriving from para-hydrogen is between 10 and 100 Hz.

### Claim 12 (depends on 11)

A method as claimed in claim 11 wherein the nmr signal from said non-zero nuclear spin nucleus in said MR imaging agent has a line width of less than 10 Hz.

### Claim 13 (depends on 12)

A method as claimed in claim 12 wherein said MR imaging agent has a molecular weight of less than 500D.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method as claimed in any one of claims 1 to 13 wherein said MR imaging agent is water-soluble.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method as claimed in any one of claims 1 to 14 wherein the chemical shift and/or the coupling constant of said non-zero nuclear spin nucleus in said MR imaging agent is sensitive to the physicochemical environment of said agent.

### Claim 16 (depends on 15)

A method as claimed in claim 15 wherein said non-zero nuclear spin nucleus in said MR imaging agent is sensitive to pH and wherein said signals are manipulated to produce an image or data indicative of pH.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method as claimed in any one of claims 1 to 16 wherein step (i) is effected in a magnetic field smaller than the earth's ambient field.

### Claim 18 (depends on 17)

A method as claimed in claim 17 wherein step (i) is effected in a magnetic field of less than 10 μT.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method as claimed in any one of claims 1 to 18 wherein in steps (iii) and (iv) said sample is exposed to a 90° pulse of radiation of a frequency selected to excite nuclear spin transitions of said non-zero nuclear spin nucleus followed by 180° pulses of said radiation, where the time interval between said 180° pulses is 2τ and the time interval between said 90° pulse and the subsequent 180° C. pulse is τ plus Δτ where Δτ is 1/(2J) where J is the coupling constant of said non-zero nuclear spin nucleus in said MR imaging agent.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method as claimed in any one of claims 1 to 18 wherein in steps (iii) and (iv) said sample is exposed to a 90° pulse of radiation of a frequency selected to excite nuclear spin transitions of said non-zero nuclear spin nucleus followed at time intervals of 21 by 180° pulses of said radiation of the same phase and where for the first n said 180° pulses said sample is simultaneously exposed to 180° pulses of radiation of a frequency selected to excite proton nuclear spin transitions, the relation between n and τ being τ=1/(4nJ) where J is the coupling constant of said non-zero nuclear spin nucleus in said MR imaging agent.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method as claimed in any one of claims 1 to 19 wherein step (i) is effected using a rhodium-based hydrogenation catalyst.

### Claim 22

Use of para-hydrogen enriched hydrogen in the manufacture of an MR imaging agent for non-proton MR imaging of a sample.

### Claim 23

Use of para-hydrogen enriched hydrogen in MR imaging of a sample.

### Claim 24 (depends on 22, 23)

Use as claimed in either one of claims 22 and 23 wherein said imaging is 13C NMR imaging of a sample.

### Claim 25

A precursor compound:
(i) containing a hydrogenatable unsaturated bond;
(ii) containing a non-hydrogen non zero nuclear spin nucleus at greater than natural isotopic abundance;
(iii) having a molecular weight below 1000OD; and
(iv) which following hydrogenation has an nmr spectrum for said non-hydrogen non zero nuclear spin nucleus which is a multiplet having a coupling constant relative to one of the hydrogens introduced by hydrogenation of 1 to 300 Hz and having a linewidth of less than 100 Hz,
and wherein when said precursor compound is a 13C enriched compound then said nucleus is a quaternary carbon nucleus.

### Claim 26 (depends on 25)

A compound as claimed in claim 25 containing the following molecular sub-units:
(i) at least one C═C or C≡C bonds;
(ii) a C, N or Si atom separated by one or two bonds from a C═C or C≡C bond, bound only to atoms the naturally most abundant isotope form of which has a nuclear spin I=0, and not coupled by a series of covalent bonds to any atoms the naturally most abundant isotopic form of which has I>½; and
(iii) at least one water-solubilizing moiety, ie. a functional group which imparts water solubility to the molecule.

### Claim 27

A reporter compound:
(i) containing at least two protons;
(ii) containing a non-hydrogen non zero nuclear spin nucleus at greater than natural isotopic abundance;
(iii) having a molecular weight below 1000D; and
(iv) having an nmr spectrum for said non-hydrogen non zero nuclear spin nucleus which is a multiplet having a coupling constant relative to one of said at least two protons 1 to 300 Hz and having a linewidth of less than 100 Hz,
and wherein when said reporter compound is a 13C enriched compound then said nucleus is a quaternary carbon nucleus.

### Claim 28 (depends on 27)

A compound as claimed in claim 27 containing the following molecular sub-units:
(i) at least one CH—CH or CH═CH moiety;
(ii) a C, N or Si atom separated by one or two bonds from a CH—CH or CH═CH moiety, bound only to atoms the naturally most abundant isotopic form of which has I=0, and not coupled by a series of covalent bounds to any atoms the naturally most abundant isotopic form of which has I>½; and
(iii) at least one water-solubilizing moiety, ie. a functional group which imparts water solubility to the molecule.

### Claim 29

A physiologically tolerable MR imaging agent composition comprising an MR imaging agent together with one or more physiologically tolerable carriers or excipients, said imaging agent containing non-hydrogen nuclei having a nuclear spin of ½, characterised in that said nuclei are polarized such that their nmr signal intensity is equivalent to a signal intensity achievable in a magnetic field of at least 0.1T.

### Claim 30 (depends on 29)

A composition as claimed in claim 29 wherein said nuclei are polarized such that their nmr signal intensity is equivalent to a signal intensity achievable in a magnetic field of at least 100T.

### Claim 31 (depends on 29, 30)

A composition as claimed in either one of claims 29 and 30 wherein said nucleus is present in an amount in excess of its natural isotopic abundance.

### Claim 32 (depends on 31)

A composition as claimed in claim 31 wherein said nucleus is present in a selected position in the molecular structure of said agent at an abundance of at least 50%.

### Claim 33 (depends on 29, 30, 31, 32)

A composition as claimed in any one of claims 29 to 32 wherein T1 for said nuclei at earth's magnetic field and at ambient temperature is at least 1 second.

### Claim 34

An apparatus for hydrogenation comprising:
a reaction chamber having therein a reaction zone, said reaction chamber having a gas inlet and a gas outlet;
a temperature controller arranged to control the temperature in said reaction zone; and
magnetic shielding arranged about said reaction zone and sufficient to cause the magnetic field in said reaction zone to be less than 10 μT.

### Claim 35 (depends on 34)

Apparatus as claimed in claim 34 wherein said reaction zone contains a particulate bed and said reaction chamber is provided with a liquid outlet below said bed and a liquid inlet above said bed.

### Claim 36 (depends on 35)

Apparatus as claimed in claim 35 comprising:
(i) a reservoir of para-hydrogen enriched hydrogen;
(ii) a reaction chamber having a reaction zone containing a particulate bed and having a first gas inlet below said bed, a first gas outlet above said bed, a solution inlet above said bed and a solution outlet below said bed;
(iii)
a gas conduit from said reservoir to said first gas inlet in the reaction chamber;
(iv) a temperature controller disposed around said reaction chamber at at least said reaction zone; and
(v) a magnetic shield disposed around said reaction chamber at at least said reaction zone.

### Claim 37

The use of para-hydrogen enriched hydrogen in the manufacture of an MR imaging agent for use in a method of diagnosis involving generation of an MR image by non-proton MR imaging.

### Claim 38

The use of a hydrogenatable compound containing a non hydrogen non zero nuclear spin nucleus in the manufacture of an MR imaging agent for use in a method of diagnosis involving generation of an MR image by non-proton MR imaging, said manufacture involving hydrogenation of said compound with para-hydrogen enriched hydrogen.
